SBIOvsARKGETF Comparison
VS
ALPS Medical Breakthroughs ETF (SBIO) belongs to the Tomorrow's Treatments segment. ARK Genomic Revolution ETF (ARKG) is part of the BioTech & Genomics segment. SBIO's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, ARKG's top sector exposures are Healthcare. SBIO is less expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.75% for ARKG. SBIO is up 23.92% year-to-date (YTD) with +$75M in YTD flows. ARKG performs better with 55.92% YTD performance, and +$33M in YTD flows. Run a side-by-side ETF comparison of SBIO and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
SBIO vs ARKG performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/11/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | SBIO ARKG | -5.45%+2.07% | +21.45%+35.35% | +23.92%+55.92% | +71.89%+73.72% | +119.59%+44.39% | +42.12%-43.98% |
| Flows | SBIO ARKG | +$31M+$57M | +$51M+$127M | +$75M+$33M | +$84M+$51M | +$56M-$523M | +$17M-$2.24B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | SBIO ARKG | +31.69%+42.98% | +30.93%+43.87% | +31.09%+43.91% | +33.90%+46.35% |
| Max drawdown | SBIO ARKG | -10.36%-13.89% | -12.63%-27.52% | -42.12%-46.41% | -52.50%-78.04% |
| Max drawdown duration | SBIO ARKG | 23d32d | 60d126d | 331d882d | 1479d1818d |
Trading data
SBIO | ARKG | |
Last sale 9/11/2026 at 1:30 PM | $63.29 | $45.56 |
| Previous close 09/10/2026 | $63.80 | $45.38 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexSBIO | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
SBIO | ARKG | |
|---|---|---|
| Last price | $63.29 | $45.56 |
| 1D performance | -0.80% | +0.40% |
| AuM | $232.85 M | $1.83 B |
| E/R | 0.5% | 0.75% |
Characteristics
SBIO | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | ALPS | Ark Investment |
| Benchmark | S-Network Medical Breakthroughs Index | - |
| N° of holdings | 104 | 31 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 30, 2014 | April 2, 2019 |
| ESG | No | No |
Advertisement
Exposure
Countries
SBIO
USA
89.23%
Other
10.77%
ARKG
USA
88.43%
Other
11.57%
Sectors
SBIO
Healthcare
100.02%
Other
-0.02%
ARKG
Healthcare
97.99%
Other
2.01%
Advertisement
Diversification
SBIO
Total weight of top 15 holdings out of 15
42.78%
ARKG
Total weight of top 15 holdings out of 15
75.55%
Top 15 holdings
Data as of July 31, 2026
SBIO
Crinetics Pharmaceuticals, Inc.
4.75%
Apogee Therapeutics, Inc.
4.48%
CG Oncology, Inc.
3.39%
Xenon Pharmaceuticals, Inc.
3.26%
Dianthus Therapeutics, Inc.
3.15%
Oruka Therapeutics, Inc.
3.14%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.56%
ACADIA Pharmaceuticals, Inc.
2.39%
Veradermics, Inc.
2.36%
Dyne Therapeutics, Inc.
2.25%
Edgewise Therapeutics, Inc.
2.23%
Relay Therapeutics, Inc.
2.22%
Denali Therapeutics, Inc.
1.97%
Structure Therapeutics, Inc.
1.84%
ARKG
10X Genomics, Inc.
9.41%
Twist Bioscience Corp.
7.74%
Tempus AI, Inc.
6.57%
CRISPR Therapeutics AG
6.30%
Personalis, Inc.
5.48%
Absci Corp.
5.15%
Guardant Health, Inc.
4.75%
Illumina, Inc.
4.75%
Eli Lilly & Co.
4.69%
CareDx, Inc.
4.31%
Natera, Inc.
4.14%
Beam Therapeutics, Inc.
3.78%
Compass Pathways Plc
3.26%
Recursion Pharmaceuticals, Inc.
2.63%
Adaptive Biotechnologies Corp.
2.58%
Frequently asked questions about SBIO and ARKG
How have the SBIO and ARKG ETFs performed in 2026?
As of September 11, 2026, SBIO is up 23.92% year-to-date (YTD), while ARKG has returned 55.92%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: SBIO or ARKG?
Year-to-date, the SBIO ETF saw +$75M in flows, compared to +$33M for ARKG.
Which ETF is more volatile: SBIO or ARKG?
Over the past year, SBIO had a volatility of 30.93%, while ARKG experienced 43.87%.
Which ETF is bigger: SBIO or ARKG?
As of September 11, 2026, SBIO holds $232.85 M in assets under management (AUM), while ARKG manages $1.83 B.
What sectors do the SBIO and ARKG ETFs invest in?
SBIO leans toward sectors like Healthcare. Meanwhile, ARKG focuses on Healthcare.
What are the top holdings of the SBIO ETF and ARKG ETF?
SBIO top holdings include Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc.. ARKG holds in its top three: 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc..
Which ETF is more diversified: SBIO or ARKG?
SBIO holds 104 securities with 42.78% of its assets in the top 15. ARKG has 31 securities and a top 15 weight of 75.55%.
Advertisement
Latest news about SBIO & ARKG
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
Advertisement
Advertisement
